432A — Cliniphar Income Statement
0.000.00%
Last trade - 00:00- ¥1bn
- ¥3bn
- ¥4bn
Annual income statement for Cliniphar, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2024 March 31st | 2025 March 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | JAS | JAS |
| Status: | Final | Final |
| Revenue | ||
| Total Revenue | 3,526 | 3,586 |
| Cost of Revenue | ||
| Gross Profit | 674 | 665 |
| Selling / General / Administrative Expenses | ||
| Unusual Expense / Income | ||
| Other Operating Expenses | ||
| Total Operating Expenses | 4,075 | 3,450 |
| Operating Profit | -549 | 135 |
| Gain / Loss on Sale of Assets | ||
| Total Net Non Operating Interest Income / Expense | ||
| Other Net Non Operating Costs | ||
| Net Income Before Taxes | -549 | 199 |
| Provision for Income Taxes | ||
| Net Income After Taxes | -613 | 190 |
| Net Income Before Extraordinary Items | ||
| Net Income | -613 | 190 |
| Adjustments to Net Income | ||
| Income Available to Common Shareholders Excluding Extraordinary Items | ||
| Income Available to Common Shareholders Including Extraordinary Items | ||
| Diluted Net Income | -613 | 190 |
| Diluted Weighted Average Shares | ||
| Basic EPS Including Extraordinary Items | ||
| Diluted EPS Including Extraordinary Items | ||
| Diluted EPS Excluding Extraordinary Items | ||
| Normalised Income Before Taxes | ||
| Normalised Income After Taxes | ||
| Normalised Income Available to Common Shareholders | ||
| Diluted Normalised EPS | -148 | 202 |
| Dividends per Share |